Recarbrio (imipenem/cilastatin/relebactam)

imipenem/cilastatin/relebactam · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recarbrio (imipenem/cilastatin/relebactam), covering 2025-05-13 to 2025-05-13. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021) [Phase 2, Phase 3]

See pricing